Water-soluble shikonin naphthazarin oxygen nucleus alkyl derivative and preparation and application methods thereof
A nuclear oxygen alkyl group and shikonin technology, which is applied in the field of water-soluble shikonin naphthalene oxyalkylated derivatives and its preparation and application, can solve the problem of water solubility of toxic side effects, increase water solubility, poor Limiting clinical application and other issues to achieve the effect of inhibiting tumor growth
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0039] The preparation of 1,4,5,8-tetramethoxy-2-[1-(N,N-dimethylaminoacetoxy)-4-methyl-3-pentenyl]naphthalene, as figure 1 As shown, this embodiment includes the following steps:
[0040] Step 1: Add shikonin (144mg, 0.50mmol), dried potassium carbonate (690mg, 5.0mmol), DMF (15ml), KI (20mg), methyl iodide (0.16ml, 2.5mmol) into a 25ml reaction vial . Under nitrogen protection, react at room temperature (25°C) for 24h. After the reaction, add water (10ml) to dilute, extract with ethyl acetate (20ml×3), wash the extract with water (15ml×2), dry over anhydrous magnesium sulfate, filter, and concentrate to dryness to obtain 139mg of crude product, which is analyzed by PTLC After separation, 121.0 mg of orange-red solid 5,8-dimethoxy-2-(1-hydroxy-4-methyl-3-pentenyl)-1,4-naphthoquinone was obtained, with a yield of 76.6%. Melting point: 56~59℃, IR(KBr): 3457, 2930, 1652, 1571, 1475, 826cm -1 . 1 HNMR (300MHz, CDCl 3 , δppm): δ7.32(s, 2H, ArH), 6.79(s, 1H, H quin ), 5.17(t...
Embodiment 2
[0044] Preparation of 1,4,5,8-tetramethoxy-2-[1-(N,N-diethylaminoacetoxy)-4-methyl-3-pentenyl]naphthalene (Ⅱ2), like figure 2 As shown, this embodiment includes the following steps:
[0045] Step one, step two, with embodiment 1 step one, step two.
[0046] Step 3 is the same as in Example 1, except that bromoacetic acid is replaced by N,N-dimethylaminoacetic acid. Obtain light yellow 1,4,5,8-tetramethoxy-2-[1-(2-bromoacetoxy)-4-methyl-3-pentenyl]naphthalene semi-cured substance 55.57mg, yield 85%.
[0047] 1 HNMR (300MHz, CDCl 3 , δppm): 6.88(s, 1H, ArH), 6.83(s, 2H, ArH), 6.42(q, 1H, J=5.4, 5.7Hz, C H =C(CH 3 ) 2 ), 5.16(t, 1H, J=7.5Hz, C H OCOCH 2 ), 3.94 (s, 3H, OCH 3 ), 3.93 (s, 3H, OCH 3 ), 3.88(s, 3H, OCH 3 ), 3.85 (d, 2H, J=6.9Hz, COC H 2 Br), 3.84(s, 3H, OCH 3 ), 2.66~2.54 (m, 2H, C H 2 CH=(CH 3 ) 2 ), 1.67 (s, 3H, C H 3 ), 1.58(s, 3H, C H 3 ).
[0048] Step 4: Dissolve 1,4,5,8-tetramethoxy-2-[1-(2-bromoacetoxy)-4-methyl-3-pentenyl]naphthalen...
Embodiment 3
[0051] 1,4,5,8-Tetramethoxy-2-{1-[2-(1-piperidinyl)acetoxy]-4-methyl-3-pentenyl}naphthalene (Ⅱ-3) preparation, such as image 3 As shown, this embodiment includes the following steps:
[0052] Step one, step two, with embodiment 1 step one, step two.
[0053] Step 3 is the same as Step 3 in Example 2.
[0054] Step 4 was the same as Step 4 of Example 2, except that piperidine was substituted for diethylamine to obtain 26.67 mg of the target compound (II-3) with a yield of 63%.
[0055] 1 HNMR (300MHz, CDCl 3, δppm): 6.86(s, 1H, ArH), 6.83(s, 2H, ArH), 6.36(q, 1H, J=5.4, 2.1Hz, C H =C(CH 3 ) 2 ), 5.17(t, 1H, J=6.0Hz, C H OCO), 3.94(s, 3H, OCH 3 ), 3.93 (s, 3H, OCH 3 ), 3.92(s, 3H, OCH 3 ), 3.85(s, 3H, OCH 3 ), 3.28(d, 2H, J=6.9Hz, COC H 2 ), 2.61~2.50 (m, 6H, CH 2 N(C H 2 CH 2 ) 2 CH 2 , C H 2 CH=(CH 3 ) 2 ), 1.66(s, 3H, C H 3 ), 163~1.58(t, 6H, COCH 2 N(CH 2 C H 2 ) 2 C H 2 ), 1.57(s, 3H, C H 3 ).
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 